Literature DB >> 36156764

Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.

Takuro Okada1, Masayuki Hashiguchi2, Satoko Hori1.   

Abstract

BACKGROUND: Signal detection in reports of spontaneous adverse drug reactions is useful in pharmacovigilance, but does not adequately consider potential confounding factors such as patient background information contained in the report data. Multiple indicators should be considered when generating safety hypotheses. AIM: The aim of this study was to evaluate whether latent class analysis (LCA) can complement conventional methods in pharmacovigilance.
METHOD: We conducted LCA of 2732 reports of adverse drug reactions involving four widely used anti-influenza neuraminidase inhibitors in the Japanese Adverse Drug Event Report (JADER) database covering April 2004 to June 2020. LCA classifies the target population into multiple clusters based on response probability. The same data was subjected to multivariate logistic regression using an adjusted reporting odds ratio.
RESULTS: LCA grouped the target population into three classes. Cluster 1 (46.4%) contained patients who developed adverse events other than neuropsychiatric events; these events were specific to adult females. Cluster 2 (28.7%) contained patients who developed abnormal behavior; these events were specific to underage males. Cluster 3 (24.8%) contained patients who developed adverse neuropsychiatric events other than abnormal behavior, such as hallucinations and convulsion; these events were specific to minors. Logistic regression of adverse events for which a signal was detected identified factors similar to those found in LCA.
CONCLUSION: LCA classified adverse events in JADER with similar incidence tendencies into the same cluster. The results included signals identified by conventional logistic regression, suggesting that LCA may be useful as a complementary tool for generating drug safety hypotheses.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Latent class analysis; Neuraminidase inhibitor drug; Signal detection; Spontaneous reporting system

Year:  2022        PMID: 36156764     DOI: 10.1007/s11096-022-01477-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  5 in total

1.  Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

Authors:  Keith B Hoffman; Andrea Demakas; Colin B Erdman; Mo Dimbil; P Murali Doraiswamy
Journal:  BMJ       Date:  2013-07-23

2.  Possible harms of oseltamivir--a call for urgent action.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Chris Del Mar
Journal:  Lancet       Date:  2009-10-17       Impact factor: 79.321

3.  Oseltamivir and abnormal behaviors: true or not?

Authors:  Takashi Yorifuji; Etsuji Suzuki; Toshihide Tsuda
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

4.  Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®.

Authors:  Rebecca E Chandler; Kristina Juhlin; Jonas Fransson; Ola Caster; I Ralph Edwards; G Niklas Norén
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

5.  Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.

Authors:  Remington L Nevin; Jeannie-Marie Leoutsakos
Journal:  Drugs R D       Date:  2017-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.